
    
      This multicenter study is open & consists of a primary & a booster phase. The study has 2
      treatment groups (Preterm & Full-term) that will receive the same vaccinations; the Full-term
      group will be the active control. Four blood samples will be collected from all subjects for
      immunogenicity analyses; 2 in the primary phase at prior to the first vaccination and one
      month after the third vaccination and 2 in the booster phase at prior to booster dose and one
      month after booster dose.
    
  